Intratumoral Fusobacterium as a prognostic and predictive biomarker in resectable colorectal cancer. The first results from the multicenter FUSOMAP project, published in ESMO Open and led by VHIO's Molecular Oncology Group, show that the presence of intratumoral Fusobacterium in surgical tumor samples identifies a clinically more aggressive subtype of colorectal cancer (CRC), characterized by a weaker immune response, limited benefit from adjuvant chemotherapy following surgery and an increased risk of disease recurrence.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: The first results from the multicenter FUSOMAP project, published in ESMO Open and led by VHIO's Molecular Oncology Group, show that the presence of intratumoral Fusobacterium in surgical tumor samples identifies a clinically more aggressive subtype of colorectal cancer (CRC), characterized by a weaker immune response, limited benefit from adjuvant chemotherapy following surgery and an increased risk of disease recurrence. These findings support the potential use of Fusobacterium as a prognostic and predictive biomarker in patients with resectable CRC.
- Ponto de atenção: intratumoral.
- Ponto de atenção: fusobacterium.
- Ponto de atenção: prognostic.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.
